Genetic barriers of resistance and impact on clinical response

MedGenMed Medscape General Medicine

Volumn 7, Issue 3, 2005, Pages

  Luber, Andrew D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE; CARBOVIR; EMTRICITABINE; PROTEINASE INHIBITOR; THYMIDINE DERIVATIVE; ZALCITABINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; CROSS RESISTANCE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MEDICAL DECISION MAKING; PATIENT COMPLIANCE; PHENOTYPE; TREATMENT FAILURE; TREATMENT OUTCOME; ANTIBIOTIC RESISTANCE; REVIEW; VIROLOGY; ANTIBIOTIC SENSITIVITY; CD4+ T LYMPHOCYTE; CLINICAL DECISION MAKING; DRUG CHOICE; HEALTH CARE AVAILABILITY; HUMAN IMMUNODEFICIENCY VIRUS; LYMPHOCYTE COUNT; PHARMACOGENETICS; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE;

EID: 34547236950     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: 10.1186/1758-2652-7-3-69     Document Type: Article

References (43)

1. Hsu RK, Wainberg MA. Do new protease inhibitors offer improved sequencing options? Issues of PI resistance and sequencing. J Acquir Immune Defic Syndr. 2004;35(suppl 1):S13-S21.
2. Kempf D, King M, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004;189:51-60.
3. Eron JJ Jr. The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials. AIDS. 1996;10(suppl 5):S11-S19.
4. Melby T, Tortell S, Thorborn D, et al. Time to appearance of NRTI-associated mutations and response to subsequent therapy for patients on failing ABC/COM. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, Illinois. Abstract 448.
5. Farthing C, Khanlou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients. Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France. Abstract 43.
6. Gallant JE, Gerondelis PZ, Wainberg MA, et al. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir Ther. 2003;8:489-506.
7. Landman R, Peytavin G, Descamps D, et al. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: the Tonus study. Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, California. Abstract 52.
8. Ruane P, Luber A, Akil B, et al. Factors influencing selection of K65R mutation among patients receiving tenofovir (TDF) containing regimens. Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France. Abstract 582.
9. D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM et al. Drug resistance mutations in HIV-1. Top HIV Med. 2003;11:92-96.
10. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003;37:113-128.
11. Lanier R, Irlbeck D, Ross L, et al. Prediction of NRTI options by linking reverse transcriptase genotypes to phenotypic breakpoints. Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, Massachusetts. Abstract 586.
12. Ruane P, Luber AD. Possible causes of early treatment failure with a novel ARV regimen. Expert Column: Medscape HIV/AIDS. 2003(2).. Available at: www.medscape.com/viewarticle/460673 Accessed May 24, 2005.
13. Hawkins T, Veikley W, St Claire R, Hey A, Guyer B, Kearney BP. Intracellular pharmacokinetics of tenofovir-DP and carbovir-TP in patients receiving triple nucleoside regimens. Program and abstracts of the 5th International Workshop on Clinical Pharmacology of HIV Therapy; April 1-3, 2004; Rome, Italy.
14. Kearney BP, Isaacson E, Sayre J, Ebrahimi R, Cheng AK. The pharmacokinetics of abacavir, a purine analogue, are not affected by tenofovir DF. Program and abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, Illinois. Abstract A-1615.
15. Piliero P, Shachoy-Clark AD, Para M, et al. A study examining the pharmacokinetics of abacavir and the intracellular carbavir triphosphate (GSK protocol CAN 10905). Program and abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, Illinois. Abstract A-1797.
16. Yuen G, Lou Y, Bumgarner NT, et al. Equivalence of plasma and intracellular triphosphate lamivudine pharmacokinetics (PK) following lamivudine (3TC) 300mg once daily compared to lamivudine 150mg twice a day in healthy volunteers. Program and abstracts of the 5th International Congress on Drug Therapy in HIV Infection; October 2001; Glasgow United Kingdom. Abstract 269.
17. Gallant JE, Rodriguez AE, Weinberg W, et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis. In: Program and abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, Illinois. Abstract H-1722a.
18. Craig C, Stone C, Bonny T, et al. Analysis of virologic failure (VF) in a clinical trial of abacavir (ABC) once daily (OAD) versus twice daily (BID) with lamivudine (3TC) and efavirenz (EFV) (Zodiac Study:CNA30021). Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, California. Abstract 551.
19. Delaunay C, Descamps D, Landman R, et al. Dynamic of selection of the K65R and M184V/I mutations in patients enrolled in Tonus trial. Program and abstracts of the 13th International HIV Drug Resistance Workshop; June 8-12, 2004; Tenerife, Canary Islands, Spain. Abstract 155.
20. Underwood MR, Ross LL, Irlbeck DM, et al. Sensitivity of phenotypic analyses for detection of K65R and M184V in mixtures with wild-type HIV-1. Program and abstracts of the 13th International HIV Drug Resistance Workshop; June 8-12, 2004; Tenerife, Canary Islands, Spain. Abstract 130.
21. Mo H, Lu L, Kempf D, Molla A. The impact of minor populations of wild-type HIV on the replication capacity and phenotype of mutant variants in a single-cycle HIV resistance assay. Program and abstracts of the 12th international HIV Drug Resistance Workshop; June 10-13, 2003; Los Cabos, Mexico. Abstract 85.
22. Miller M, White KL, Petropoulous CJ, Parkin NT. Decreased replication capacity of HIV-1 clinical isolates containing K65R or M184V RT mutations. Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston Massachusetts. Abstract 616.
23. Weber J, Chakraborty B, Miller MD, Quinones-Mateu ME. Diminished relative fitness of primary HIV-1 isolates harboring the K65R mutation. Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, California. Abstract 637.
24. Parikh U, Koontz D, Sluis-Cremer N, et al. K65R: a multinucleoside resistance mutation of increasing prevalence exhibits bidirectional phenotypic antagonism with TAM. Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004;San Francisco, California. Abstract 54.
25. Winston A, Pozniac A, Gazzard B, Nelson M. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase? Program and abstracts of the 12th international HIV Drug Resistance Workshop; June 10-13, 2003; Los Cabos, Mexico. Abstract 137.
26. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, California. Abstract 51.
27. Barrios A, Negredo E, Vilaro-Rodriguez J, et al. Safety and efficacy of a QD simplification regimen. Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, California. Abstract 566.
28. Podzamczer D, Ferrer E, Gatell JM, et al. Early virologic failure and occurrence of resistance in naive patients receiving tenofovir, didanosine and efavirenz. Program and abstracts of the 13th International HIV Drug Resistance Workshop; June 8-12, 2004; Tenerife, Canary Islands, Spain. Abstract 156.
29. Gallant JE, Staszewski S, Pozniak AL, et al; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
30. US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. April 7, 2005. Available at: http://aidsinfo.nih.gov/guidelines/adult/AA_040705.pdf Accessed May 24, 2005.
31. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr. 1990;3:743.
32. Squires K, Pozniak AL, Pierone G Jr, et al, and the Study 907 Team. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med. 2003;139:313-320.
33. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865-1873.
34. Delaugerre C, Rohban R, Simon A, et al. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol. 2001;65:445-448.
35. Gazzard BG, DeJesus E, Cahn P, et al. Abacavir (ABC) once daily (OAD) plus lamivudine (3TC) OAD in combination with efavirenz (EFV) OAD is well-tolerated and effective in the treatment of antiretroviral therapy (ART) naive adults with HIV-1 infection (ZODIAC study: CNA30021). Program and abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, Illinois. Abstract H1722b.
36. Bae AS, Waters JM, Margot NA, Borroto-Esoda K, Miller M. Pre-existing L74V is a risk factor for virologic non-response and development of K65R in patients taking tenofovir DF. Program and abstracts of the 13th International HIV Drug Resistance Workshop; June 8-12, 2004; Tenerife, Canary Islands, Spain. Abstract 158.
37. MacManus S, Yates PJ, Elston RC, White S, Richards N, Snowden W. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS. 2004;18:651-655.
38. Bongiovanni M, Bini T, Adorni F, et al. Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations. Antivir Ther. 2003;8:209-214.
39. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2003;47:350-359.
40. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004;35:22-32.
41. Colonno R, Rose R, McLaren C, Thiry A, Parkin N, Friborg J. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis. 2004;189:1802-1810.
42. Cammack N et al. RO033-4649: A new HIV-1 protease inhibitor designed for both activity against resistant virus isolates and favorable pharmacokinetic properties. Program and abstracts of the 13th International HIV Drug Resistance Workshop; June 8-12, 2004; Tenerife, Canary Islands, Spain. Abstract 7.
43. Gathe J, Podzamczer D, Johnson M, et al. Once-daily vs. twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 48 week results. Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, California. Abstract 570.